结核病治疗市场 - 全球产业规模、份额、趋势、机会和预测，按疾病类型、按疗法、按给药途径、按剂型、按配销通路、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球结核病治疗市场价值为 21.8 亿美元，预计到 2030 年将达到 29.4 亿美元，复合年增长率为 5.05%。该市场是传染病治疗领域的一个重要领域，受益于持续的全球需求，尤其是抗药性结核病发病率的上升。儘管结核病治疗领域的利润率一直较低，但它仍具有巨大的公共卫生价值和长期商业潜力。在全球病例数量稳定以及捐助者和公共机构大量资金的支持下，各国政府、卫生机构和製药公司越来越重视开发创新结核病治疗方法。随着下一代药物开发（尤其是二线疗法）的兴起，能够平衡成本效益、适应监管环境并建立策略合作的公司将能够确保可持续的竞争优势。

关键市场驱动因素

全球结核病负担沉重

主要市场挑战

药物研发资金不足且商业激励有限

主要市场趋势

转向更短、更有效的治疗方案

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：结核病治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型（活动性结核病、潜伏性结核病）
  • 按疗法（一线疗法、二线疗法）
  • 依给药途径（口服、肠胃外、其他）
  • 按剂型（片剂、胶囊、注射剂、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美结核病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲结核病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太结核病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲结核病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲结核病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球结核病治疗市场：SWOT 分析

第 14 章：竞争格局

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Tuberculosis Therapeutics Market was valued at USD 2.18 billion in 2024 and is projected to reach USD 2.94 billion by 2030, growing at a CAGR of 5.05%. Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development-particularly in second-line therapies-on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.

Key Market Drivers

High Global Burden of Tuberculosis

The global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.

Key Market Challenges

Inadequate Funding and Limited Commercial Incentives for Drug Development

The concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.

Key Market Trends

Shift Toward Shorter, More Effective Treatment Regimens

There is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.

Key Market Players

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

Report Scope:

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

• Active TB
• Latent TB

Tuberculosis Therapeutics Market, By Therapy:

• First-Line Therapy
• Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

• Oral
• Parenteral
• Others

Tuberculosis Therapeutics Market, By Dosage Form:

• Tablets
• Capsules
• Injection
• Others

Tuberculosis Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Tuberculosis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Tuberculosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Active TB, Latent TB)
  • 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy
  • 6.2.3. By Route of Administration
  • 6.2.4. By Dosage Form
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Dosage Form
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Dosage Form
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Dosage Form
      • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy
  • 7.2.3. By Route of Administration
  • 7.2.4. By Dosage Form
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Dosage Form
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Tuberculosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Dosage Form
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Tuberculosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Dosage Form
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Tuberculosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Dosage Form
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Dosage Form
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy
  • 8.2.3. By Route of Administration
  • 8.2.4. By Dosage Form
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Tuberculosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Dosage Form
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Tuberculosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Dosage Form
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Dosage Form
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Dosage Form
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Dosage Form
      • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy
  • 9.2.3. By Route of Administration
  • 9.2.4. By Dosage Form
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Dosage Form
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Dosage Form
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Dosage Form
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy
  • 10.2.3. By Route of Administration
  • 10.2.4. By Dosage Form
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Dosage Form
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Dosage Form
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Dosage Form
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Johnson & Johnson Services, Inc.
• 14.3. Eli Lilly and Company
• 14.4. Mylan Inc.
• 14.5. Teva Pharmaceutical Industries Ltd
• 14.6. Sanofi
• 14.7. Novartis AG
• 14.8. Sun Pharmaceutical Industries Ltd
• 14.9. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer